Have a feature idea you'd love to see implemented?
Let us know!
RVNC Revance Therapeutics Inc
Price (delayed)
$3.84
Market cap
$402.83M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.94
Enterprise value
$827.22M
Revance Therapeutics, Inc. is a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection. DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide
Highlights
The EPS has soared by 62% YoY and by 39% QoQ
RVNC's net income has soared by 55% YoY and by 36% QoQ
Revance Therapeutics's equity has plunged by 54% YoY and by 26% from the previous quarter
Revance Therapeutics's quick ratio has decreased by 27% YoY
Key stats
What are the main financial stats of RVNC
Market
Valuations
Earnings
Shares outstanding
104.9M
Market cap
$402.83M
Enterprise value
$827.22M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
1.62
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.35
Revenue
$247M
EBIT
-$159.87M
EBITDA
-$153.79M
Free cash flow
-$194.91M
Per share
Balance sheet
Liquidity
EPS
-$1.94
Free cash flow per share
-$1.87
Book value per share
-$1.56
Revenue per share
$2.37
TBVPS
$4.36
Total assets
$461.56M
Total liabilities
$624.59M
Debt
$483.45M
Equity
-$163.03M
Working capital
$249.64M
Debt to equity
-2.97
Current ratio
4.12
Quick ratio
2.91
Net debt/EBITDA
-2.76
Margins
Efficiency
Dividend
EBITDA margin
-62.3%
Gross margin
72.6%
Net margin
-74.7%
Operating margin
-67.8%
Return on assets
-38%
Return on equity
N/A
Return on invested capital
-20.7%
Return on capital employed
-41.9%
Return on sales
-64.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RVNC stock price
How has the Revance Therapeutics stock price performed over time
Intraday
1.05%
1 week
-10.9%
1 month
-27.27%
1 year
-46.89%
YTD
-56.31%
QTD
-26.01%
Financial performance
How have Revance Therapeutics's revenue and profit performed over time
Revenue
$247M
Gross profit
$179.35M
Operating income
-$167.55M
Net income
-$184.44M
Gross margin
72.6%
Net margin
-74.7%
Revance Therapeutics's net margin has surged by 63% YoY and by 37% QoQ
RVNC's net income has soared by 55% YoY and by 36% QoQ
The operating margin has soared by 51% year-on-year and by 5% since the previous quarter
The operating income rose by 41% YoY and by 3.1% QoQ
Growth
What is Revance Therapeutics's growth rate over time
Valuation
What is Revance Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
1.62
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.35
The EPS has soared by 62% YoY and by 39% QoQ
Revance Therapeutics's equity has plunged by 54% YoY and by 26% from the previous quarter
The P/S is 100% lower than the 5-year quarterly average of 462.1 and 23% lower than the last 4 quarters average of 2.1
RVNC's revenue is up by 21% YoY and by 2.4% from the previous quarter
Efficiency
How efficient is Revance Therapeutics business performance
The ROS has soared by 67% YoY and by 41% QoQ
The ROIC has soared by 63% YoY and by 41% from the previous quarter
The ROA has increased by 48% YoY and by 33% QoQ
Dividends
What is RVNC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RVNC.
Financial health
How did Revance Therapeutics financials performed over time
The total assets is 26% less than the total liabilities
Revance Therapeutics's quick ratio has decreased by 27% YoY
The total assets has contracted by 13% YoY and by 7% from the previous quarter
Revance Therapeutics's equity has plunged by 54% YoY and by 26% from the previous quarter
The debt to equity is up by 35% year-on-year and by 22% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.